UNIT 20.9 ErbB2 Transgenic Mice: A Tool for Investigation of the Immune Prevention and Treatment of Mammary Carcinomas
Published Online: 1 AUG 2008
Copyright © 2008 by John Wiley & Sons, Inc.
Lab Protocol Title
Current Protocols in Immunology
How to Cite
Quaglino, E., Mastini, C., Forni, G. and Cavallo, F. 2008. ErbB2 Transgenic Mice: A Tool for Investigation of the Immune Prevention and Treatment of Mammary Carcinomas. Current Protocols in Immunology. 82:20.9:20.9.1–20.9.10.
- Published Online: 1 AUG 2008
- Published Print: AUG 2008
The epidermal growth factor receptor belongs to a superfamily of receptor tyrosine kinases (RTK) that includes ErbB2. ErbB2 is involved in normal physiological processes, such as embryogenesis, cell proliferation, differentiation, adhesion motility, and apoptosis, while its malfunction or overexpression is responsible for development defects, diabetes, and cancer. The human ortholog of ErbB2 is referred as Her-2 (human ErbB2) while the rat ortholog is referred as neu (rat ErbB2). As ErbB2 is directly involved in carcinogenesis, mice transgenic for the rat neu oncogene allow straightforward assessment of the ability of drugs and vaccines to inhibit the progression of neu-driven cancer. Information from this model may provide indications on the efficacy of similar treatments in patients. This commentary provides key information regarding the use of these transgenic mouse models for evaluation of the efficacy of anti-tumor strategies. Curr. Protoc. Immunol. 82:20.9.1-20.9.10. © 2008 by John Wiley & Sons, Inc.
- mammary carcinogenesis;
- genetically engineered mice;
- BALB-neuT-KO mice;
- neu transgenic mice;
- Her-2 transgenic mice